The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review)
In cardiac surgery with cardiopulmonary bypass (CPB) is a common complication. The incidence of this complication in cardiac surgery patients is estimated at about 10%. For this reason, the introduction of a patient blood management (PBM) in cardiac surgery is extremely relevant. Antifibrinolytic th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2024-08-01
|
| Series: | Вестник анестезиологии и реаниматологии |
| Subjects: | |
| Online Access: | https://www.vair-journal.com/jour/article/view/1038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343556827742208 |
|---|---|
| author | V. Yu. Medvedeva K. N. Khrapov A. A. Khryapa K. Yu. Kankova |
| author_facet | V. Yu. Medvedeva K. N. Khrapov A. A. Khryapa K. Yu. Kankova |
| author_sort | V. Yu. Medvedeva |
| collection | DOAJ |
| description | In cardiac surgery with cardiopulmonary bypass (CPB) is a common complication. The incidence of this complication in cardiac surgery patients is estimated at about 10%. For this reason, the introduction of a patient blood management (PBM) in cardiac surgery is extremely relevant. Antifibrinolytic therapy is a key pharmacological tool of a multimodal PBM in cardiac surgery with CPB. The use of antifibrinolytics (tranexamic acid (TXA) and epsilon aminocaproic acid (EACA)) is standard practice in complex cardiac surgery with CPB. However, there is currently ongoing discussion regarding the search for the optimal dose of EACA and TXA to achieve an effective concentration in blood plasma in order to inhibit fibrinolysis with the minimization of adverse events. The use of aprotinin has a number of potential advantages, but its use in routine clinical practice is significantly limited. This review presents modern approaches to antifibrinolytic therapy, examines the mechanisms of action of the main drugs, highlights the side effects associated with the use of antifibrinolytic agents. |
| format | Article |
| id | doaj-art-ffecd8d511d7491c906bb49c7b4c968f |
| institution | Kabale University |
| issn | 2078-5658 2541-8653 |
| language | Russian |
| publishDate | 2024-08-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Вестник анестезиологии и реаниматологии |
| spelling | doaj-art-ffecd8d511d7491c906bb49c7b4c968f2025-08-20T03:42:56ZrusNew Terra Publishing HouseВестник анестезиологии и реаниматологии2078-56582541-86532024-08-012149210310.24884/2078-5658-2024-21-4-92-103700The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review)V. Yu. Medvedeva0K. N. Khrapov1A. A. Khryapa2K. Yu. Kankova3Pavlov UniversityPavlov UniversityPavlov UniversityPavlov UniversityIn cardiac surgery with cardiopulmonary bypass (CPB) is a common complication. The incidence of this complication in cardiac surgery patients is estimated at about 10%. For this reason, the introduction of a patient blood management (PBM) in cardiac surgery is extremely relevant. Antifibrinolytic therapy is a key pharmacological tool of a multimodal PBM in cardiac surgery with CPB. The use of antifibrinolytics (tranexamic acid (TXA) and epsilon aminocaproic acid (EACA)) is standard practice in complex cardiac surgery with CPB. However, there is currently ongoing discussion regarding the search for the optimal dose of EACA and TXA to achieve an effective concentration in blood plasma in order to inhibit fibrinolysis with the minimization of adverse events. The use of aprotinin has a number of potential advantages, but its use in routine clinical practice is significantly limited. This review presents modern approaches to antifibrinolytic therapy, examines the mechanisms of action of the main drugs, highlights the side effects associated with the use of antifibrinolytic agents.https://www.vair-journal.com/jour/article/view/1038fibrinolysis inhibitorsbleedingaminocaproic acidtranexamic acidaprotinincardiac surgery with cardiopulmonary bypass (cpb) |
| spellingShingle | V. Yu. Medvedeva K. N. Khrapov A. A. Khryapa K. Yu. Kankova The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review) Вестник анестезиологии и реаниматологии fibrinolysis inhibitors bleeding aminocaproic acid tranexamic acid aprotinin cardiac surgery with cardiopulmonary bypass (cpb) |
| title | The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review) |
| title_full | The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review) |
| title_fullStr | The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review) |
| title_full_unstemmed | The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review) |
| title_short | The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review) |
| title_sort | use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass literature review |
| topic | fibrinolysis inhibitors bleeding aminocaproic acid tranexamic acid aprotinin cardiac surgery with cardiopulmonary bypass (cpb) |
| url | https://www.vair-journal.com/jour/article/view/1038 |
| work_keys_str_mv | AT vyumedvedeva theuseoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview AT knkhrapov theuseoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview AT aakhryapa theuseoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview AT kyukankova theuseoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview AT vyumedvedeva useoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview AT knkhrapov useoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview AT aakhryapa useoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview AT kyukankova useoffibrinolysisinhibitorsincardiacsurgerywithcardiopulmonarybypassliteraturereview |